ArticleBritish journal of pharmacology2012

Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo.

S Ackler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.